Moreover, our data suggest that HER2-positive breast cancer patients who clinically benefited from neoadjuvant metformin were particularly sensitive to its metabolic effects on mitochondrial fatty acid β-oxidation. This evidence concerns the gene ERBB2 and breast carcinoma.